1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 5, 2001
Commission File Number 1-09623
IVAX CORPORATION
Florida 16-1003559
- ------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
4400 Biscayne Boulevard, Miami, Florida 33137
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(305) 575-6000
----------------------------------------------------
(Registrant's telephone number, including area code)
2
ITEM 2 - ACQUISITION OR DISPOSITION OF ASSETS
On May 31, 2001 IVAX Corporation launched a tender offer in Chile for all of the
outstanding shares of Laboratorio Chile S.A., and simultaneously launched a
tender offer in the United States for all of the outstanding American Depository
Shares ("ADSs") and all of the outstanding shares of Laboratorio Chile held by
U.S. holders. On July 6, 2001, IVAX announced the successful completion of the
tender offers and its acceptance of all validly tendered shares and ADSs of
Laboratorio Chile S.A., representing approximately 99.6% of the outstanding
shares, including shares represented by ADSs. IVAX purchased shares of common
stock for US$1.25 per share and ADSs for US$25.00 per ADS. The aggregate
purchase price of approximately $394,000,000 was paid from IVAX' cash on hand.
Laboratorio Chile was, at the time of purchase, the largest Chilean
pharmaceutical company in revenue terms and also among the major pharmaceutical
companies in Argentina and Peru. Laboratorio Chile manufactures, markets and
sells a broad line of more than 900 branded and brand equivalent products in
Chile, Argentina and Peru. Its main products are to treat respiratory and
infectious diseases, but it also has strong franchises with cardiovascular,
neurological and gynecological products.
ITEM 7 - FINANCIAL STATEMENTS AND EXHIBITS
The financial statements required by this item will be filed no later than 60
days after the date that the initial report on Form 8-K must be filed.
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IVAX CORPORATION
Date: July 20, 2001 By: /s/ Thomas E. Beier
------------------------------------
Thomas E. Beier
Senior Vice President-Finance
Chief Financial Officer
3